Clinicopathological Features and Prognostic Implication of Gastric Carcinoma with Lymphoid Stroma

Table 1

Main characteristics of the eligible studies.

	Location	Patient’s group	Number of patients	EBV positive rate		Location	Patient’s group	Number of patients	EBV positive rate
Chang 2000	Korea	GCLS w/EBV+	30	66.7%	Lopes 2004	Brazil	GCLS	7	57.1%
		GCLS w/EBV-	15		Lu 2004	China	GCLS	17
Chang 2001	Korea	GCLS	14	50.0%			Non-GCLS	64
		Non-GCLS	292	3.4%	Min 2016	Korea	GCLS	145	85.5%
Cheng 2015	China	GCLS w/EBV+	8		Mohri 2017	Japan	GCLS	15	66.7%
		Non-GCLS w/EBV +	45		Ohtani 2009	Japan	GCLS	24	91.7%
Cho 2003	Korea	GCLS	9	77.8%			Non-GCLS	35	5.7%
		Non-GCLS	21	19.0%	Osumi 2019	Japan	GCLS	80	75.0%
Cho 2004	Korea	GCLS	24	79.2%	Otsuji 2004	Japan	GCLS	31
		Non-GCLS	23	8.7%			Non-GCLS w/PD	136
Gonzalez 2017	USA	GCLS	13				Non-GCLS w/WD	799
Hirai 2016	Japan	GCLS	23		Park 2015	Korea	GCLS	46	80.4%
Hissong 2018	USA	GCLS	31	22.6%			Non-GCLS	4236	6.5%
Huang 2013	Taiwan	GCLS in EGC	31		Ramos 2017	Brazil	GCLS	7
		Non-GCLS in EGC	520				Non-GCLS	248
		GCLS in AGC	191		Ribeiro 2017	Portugal	GCLS	3	100.0%
		Non-GCLS in AGC	1217		Selves 1996	France	GCLS	6	66.7%
Huang 2014	Taiwan	GCLS w/EBV+	18		Setia 2019	USA	GCLS	17	64.7%
		Non-GCLS w/EBV +	33		Shin 2017	Korea	GCLS	70
Huh 2016	Korea	GCLS	41	72.2%			Non-GCLS	1626
		Non-GCLS	3344		Song 2010	USA	GCLS w/EBV+	53
Jing 1997	Japan	GCLS	8	37.5%			Non-GCLS w/EBV +	18
Kang 2016	Korea	GCLS	60		Tobo 2013	Japan	GCLS	104	75.0%
		Non-GCLS	60				Non-GCLS	29	0.0%
Lim 2015	Korea	GCLS	274	86.1%	Wu 2000	Taiwan	GCLS w/EBV+	11
		Non-GCLS	822				Non-GCLS w/EBV +	19
Lim 2017	Korea	GCLS	241	89.2%			Non-GCLS w/EBV-	120
		Non-GCLS	1219		Yanagi 2019	Japan	GCLS	43	60.5%
Lim 2018	Korea	GCLS	40	90.0%	Yuen 1994	Hong Kong	GCLS	7	28.6%

In gastric carcinoma with lymphoid stroma; EBV, Epstein-Barr virus; GCLS, gastric carcinoma with lymphoid stroma; w/, with; EGC, early gastric carcinoma; AGC, advanced gastric carcinoma; PD, poorly differentiated; WD, well differentiated.